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Aim Toassess the feasibility of administering PatientReportedOutcomesMeasures (PROMs) in patients treatedwith ablation
for cardiac arrhythmias, and to conduct the first stage of development and testing of a new PROM tool.
Methods
and results
A new tool was developed by a multidisciplinary team and tested alongside an adaptation of the patient perception of
arrhythmia questionnaire (PPAQ) and EQ-5D-5L in a multicentre retrospective audit involving 791 consecutive
cardiac arrhythmia patients treated with catheter ablation at three UK centres over 13 months. Data were recorded
in theNational Cardiac RhythmManagement Database, part of the National Institute for Cardiovascular Outcomes Re-
search. The response rate was 71.9% (n ¼ 569). Patients reported significant improvements across all outcomes and
impacts, with reductions in symptoms of 51.7% (heart racing), 33.9% (fatigue) 31.8% (heart flutters), 43.5% (dizziness),
38.6%(breathlessness), 44.2%(chestpressure), 33.1%(trouble concentrating), 15.9%(headache), 28.3%(neckpressure),
and23.4% (fainting) (P, 0.001). Themeannumberof social days affected reducedby7.49days/month (P, 0.001);mean
work/school days affected/month reduced by 6.26 (P, 0.001); mean GP/hospital visits reduced by 1.36 days/month
(P, 0.001). The procedure met patient expectations in 72% of responders.
Conclusions The high response rate suggests that the use of PROMs in this patient group is feasible, with rates equalling those of the
National PROMs Programme. The results showed that patients experienced significant improvements in their quality of
life following ablation, while feedback allowed the tools to be improved. Further work is required to validate these tools;
however, the findings suggest that PROMs could be useful in the audit of ablation techniques.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Introduction
The effectiveness of medical interventions has traditionally been
measured from a clinical perspective, looking at factors including
complication and mortality rates, with clinical improvements
assessed by healthcare staff. However, emphasis is increasingly
being placed on gaining patients’ own perceptions of treatment
success1,2 using methods such as Patient Reported Outcome Mea-
sures (PROMs). Patient Reported OutcomeMeasures are question-
naires which are administered both before and after a procedure or
treatment to measure changes in a patient’s’ opinion of their health
status following an intervention. A PROM tool may be generic,
such as EQ5D,3 which assesses general health status and may be
used in any population, or disease-specific, assessing the impact of
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a particular condition or disease on a patient. Disease-specific mea-
sures are often used to identify clinically important treatment
related changes to an individual’s health and wellbeing, while
generic tools can compare outcomes across different treatment
and patient groups. As they have different strengths, both types
may be administered during a health outcomes assessment. Patient
Reported Outcome Measures have the potential to drive changes
within theNational Health Service (NHS),4 supporting the provision
of patient-orientated care with benefits including reduced cost and
improved safety and quality outcomes.5,6
The fieldof cardiac ablation is an ideal area for the useof PROMs as
these procedures are often aimed at improving or abolishing specific
symptoms. Estimated to affect over 1million people in theUK alone,7
cardiac arrhythmias are associated with features including nausea,
fatigue, heart racing, breathlessness, and chest pain. Symptoms may
be difficult to quantify clinically but have significant adverse effects
on health and the quality of life.8–10 Many patients report suffering
a lack of independence and for many, symptoms lead to a loss of
time at work and impaired ability to carry out normal daily routines.
Furthermore, anti-arrhythmic drugs themselves can cause un-
pleasant side effects,11 including worsening arrhythmia, dizziness,
and photosensitivity. Currently, no disease-specific tools have been
validated in the UK to assess the patient-reported outcomes of abla-
tion procedures in patients with non-specific cardiac arrhythmias;
therefore, the full impact of these conditions remains unclear.
The purpose of this study was to develop a short disease-specific
tool and adapt the longer patient perception of arrhythmia question-
naire (PPAQ) developed byWood et al.12 for use in a UK population
of patients treated with ablation for a symptomatic arrhythmia.
Furthermore, this study aimed to pilot these together with the
EQ-5D-5L in amulticentre audit to explore the feasibilityof obtaining
PROM data in this population. The secondary aims were to identify
weaknesses in the tools and administration process to improve the
methods and further develop the questionnaires.
Methods
Questionnaires
The cardiac ablation PROM tool comprised three individual question-
naires usedas a single tool. Thefirst, a short arrhythmia-specificquestion-
naire,wasdeveloped following literaturereviewsand research,with input
from a multidisciplinary team of cardiac consultants, arrhythmia nurses,
clinical advisors, and research scientists. This tool explored patients’
treatment expectations prior to the procedure and whether these
were subsequently met. It also considered the number of ablations
received and investigated unexpected complications arising from the
procedure. The second element of the tool comprised of a modification
of the arrhythmia-specific PPAQ questionnaire developed by Wood
et al.12 Thiswasoriginally developedusing techniques including formative
research, exploratory factor analysis, expert review, and pilot study. Fol-
lowing adaptations for use in a UK population, this updated tool included
seven domains covering severity of symptoms, regularity and length of
adverse features, impact on social life and normal routine, arrhythmia-
related visits to GP/hospital, and impact on life.
The third element was the generic EQ-5D-5L questionnaire, a vali-
dated tool consisting of five domains assessing mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. Each domain includes
five levels of response ranging from no problems to severe problems. It
also has a visual analogue scale (VAS) inviting patients to rate their
health on a scale of 0–100 with 0 being the worst health imaginable
and 100 being the best imaginable. Supporting documentation, including
the cover letter and consent form, was also developed, including Welsh
translations. A contact name and telephone number were provided for
patients’ queries.
Study design
The tools were designed to be completed by patients before the proced-
ureandagain at aminimumofeightweekspost-procedure.However, due
to time constraints of the pilot, a retrospective study design was used,
whereby patients were sent pre- and post-procedure questionnaires at
the same time and asked to complete the pre-procedure questionnaires
frommemory. Reminders containing copies of the documentation were
sent out 16–29 days after the first contact to non-responders.
Participants
A cohort of 800 patients who had received radiofrequency ablation
therapy for a cardiac arrhythmia prior to the start of the study on 1 No-
vember 2010 from three treatment centres were retrospectively identi-
fied for inclusion. Participantswere required to (i) have received a cardiac
ablation a minimum of 8 weeks prior to the study; (ii) be aged ≥17 at the
time of the study; and (iii) have had their details entered onto theCentral
Cardiac Audit Database (CCAD), part of the National Institute for Car-
diovascular Outcomes Research. Consecutive patients were enrolled
from each site: Queen Elizabeth Hospital, University Hospitals Birming-
ham (400 patients); The Freeman Hospital, Newcastle Upon Tyne
NHS Trust (200 patients), and University Hospital of Wales, Cardiff &
Vale University Health Board (200 patients). Three patients from Bir-
mingham and six from Newcastle were subsequently removed from
the study as they were determined to be duplicate patients who had
moved house or been retreated, or were identified as deceased; this
left 791 patients in the study group.
Data collection, storage, and analysis
Responses were sent to Cedar; an NHS organization independent of the
treatment clinics, for data entry and logged onto the CCADwith 15% of
entries checked for accuracy. The CCAD is a clinical audit facility which
collects information on cardiac procedures within the UK. It is used as
a confidential data collection point allowing comparative reporting
between treatment centres, data quality reporting, and mortality track-
ing, with all UK ablation centres highly encouraged to submit procedural
data. A specially designed extension to the CCAD was developed to
allow the linkageof PROMs returns to existing clinical datawhile retaining
patient anonymity. Clinical data and PROMs datawere stored separately
What’s new?
† A Patient Report Outcome Measures for use in cardiac
arrhythmia patients undergoing radiofrequency ablation
treatment.
† Collecting Patient-Reported Outcomes in patients treated
with ablation techniques for cardiac arrhythmias is a feasible
way of measuring procedural success.
† Themajority of responders were positive about the outcome
of their ablation, with over 72% of patients reporting that the
procedure had met their expectations.
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to prevent clinical staff accessing individual identifiable PROMdata at any
stage.
Datawere analysedusing SPSS (IBMSPSSStatisticsVersion21) and a 5%
significance level was used. For statistical analysis, missing values were
excluded on a pairwise basis. EQ-5D questionnaires were scored using
the EQ-5D-5L Crosswalk index value calculator.13 Differences between
pre- and post-procedure nominal variables (e.g. presence or absence of
symptoms) were analysed using McNemar’s test. Differences between
pre- and post-procedure means of continuous data were analysed using
a paired-sample t-tests, where the appropriateness of parametric tests
was in question, a related-sampleWilcoxon signed-rank test was used.
Results
Responses
An initial response rate of between 45% and 50% was achieved from
each centre following initial mailing, rising to a rate of 70–75% from
each centre after reminders had been sent, with a final total of 569
analysable responses (71.9%). Three responses were received after
the studyenddate andwereexcluded fromanalysis. In 12cases, a nar-
rative response was received without a completed questionnaire
with reasons cited for non-completion including death, ill health,
and on-going treatment. One letter was returned to the sender.
Fifteen telephone enquirieswere received regarding the question-
naires. In five cases, this was to inform the team that patients were
unable to complete the questionnaire due to ill health (two patients),
death (two patients), and emigration (one patient). One enquiry was
received from a patient requiring advice regarding ongoing health
issues; this patientwas referred to a contact at the relevant treatment
centre. Other enquiries regarded issues such as questions clarif-
ication and concerns including whether other peoples’ opinions
(e.g. clinicians/family members) should be taken into account.
Data
Themean age of the 569 respondents was 57.8 years, and 315 (55%)
were males (Table 1). Responses were received from patients with
ten different arrhythmia substrates although the majority (70.3%)
fell into just three categories (flutter, atrial fibrillation, and atrio-
ventricular nodal re-entrant tachycardia).
Responding patients reported an improvement across all symp-
toms investigated by the questionnaires (Figure 1) (symptoms
reported by ,60% of patients pre-procedure; headache, trouble
concentrating, neck pounding, and fainting, not illustrated). There
was a statistically significant difference in the proportion of patients
reporting symptoms (mild, moderate, and severe combined)
before the procedure compared with after the procedure (P,
0.001 for all 10 symptoms). Therewas also a reduction in the severity
for those who remained symptomatic. The largest difference in
symptom prevalence between the pre- and post-procedure
reported symptomswas in heart racing [pre-procedure 510 patients
(89.6%), post-procedure 225 patients (39.5%)] and the smallest was
in headache [pre-procedure 216 patients (38.0%), post-procedure
154 patients (27.1%)]. Table 2 further illustrates changes in patient
symptoms within the three largest arrhythmia substrate groups.
Within these groups, atrio-ventricular nodal re-entrant tachycardia
(AVNRT) patients were most likely to report a complete abolition
of symptoms. However, the picture for symptom improvement
was more mixed across the substrates, and with the exception of
chest pressure, over 50% of patients from each group reported an
improvement in symptom severity.
Every symptom studied showed a reduction in the proportion of
patients reporting both severe and moderate symptoms (not com-
bined). Again heart racing showed the largest improvement after
treatment (Figure 2) with patients reporting severe and moderate
heart racing reducing from 342 (63.7%) and 134 (25.0%) to 43
(8.3%) and 69 (13.3%), respectively. The smallest reduction was
reported for headache with severe and moderate headaches redu-
cing from 39 (8.5%) and 63 (13.8%) to 14 (2.8%) and 41 (8.3%),
respectively.
The responses showed a large decrease in both frequency of ar-
rhythmia episodes and length of episode in those patients who still
suffered arrhythmia following ablation. Pre-ablation, 15 patients
(2.6%) “Never” suffered episodes of arrhythmia, rising to 270
patients (47.5%) following the procedure (Figure 3). The length of
episode was significantly reduced, with patients experiencing
average episodes lasting ≥1 h reducing from 292 (51.3%) pre-
ablation to 29 patients (5.1%) post-ablation (Figure 4).
Changes in the impact of symptoms
on functional ability
The PROMtool investigated the number of days’ impact on social ac-
tivities, days missed at work/school/college, and number of GP/hos-
pital visits in the 30 days prior to the procedure and the 30 days prior
to receiving the questionnaires post procedure. There was a reduc-
tion in the mean score after ablation in all the three impact para-
meters for the total participant group (P, 0.001) and across all 10
substrates (Table 3). For social days affected, statistically significant
differences (P, 0.05) were observed in 9 of 10 substrates; for
both work/school days affected and GP/hospital visits, statistically
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Patient data by substrate
Substrate Number (%) Mean age
(range)
Male (%)
Atrial flutter—
common
(c/Flutter)
143 (25.2) 63.1 (26–88) 105 (73.4)
AF 131 (23.0) 59.6 (28–79) 95 (72.5)
AVNRT 126 (22.1) 50.1 (18–86) 42 (33.3)
Complete AVN 42 (7.4) 74.7 (50–88) 18 (42.9)
Overt accessory
pathway (oAP)
34 (6.0) 47.1 (18–81) 14 (41.2)
Atrial tachycardia
(AT)
28 (5.0) 59.6 (17–85) 9 (32.1)
Ventricular
tachycardia (VT)
20 (3.5) 57.2 (22–80) 12 (60.0)
Atypical flutter
(u/Flutter)
18 (3.2) 57.1 (27–78) 7 (38.9)
Concealed AP (cAP) 15 (2.6) 36.4 (17–55) 7 (46.7)
Ventricular Ectopics
(VE)
12 (2.1) 53.2 (26–75) 7 (58.3)
Total 569 (100) 57.8 (17–88) 315 (55)
K.L. Withers et al.1628
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significant differences (P, 0.05) were observed in 6 of 10 substrates
(Table 3).
The largest improvements in days affected (either social or work/
school) were observed in atrio-ventricular nodal, AVN [a reduction
of 8.48 social days affected (P ¼ 0.002); 11.90 reduction in work/
school days affected (P ¼ 0.001)] and VE substrates [a reduction of
9.36 social days affected (P ¼ 0.011); a reduction of 10.30 work/
school days affected (P ¼ 0.016)]; VE also accounted for the
highest significant improvement in number of GP/hospital visits
(3.36 reduction (P ¼ 0.026)).
EQ5D data
The complete index values for both pre- and post-procedure ques-
tionnaires were available for 498 patients; these showed improve-
ments in general health in 349 patients (70.1%). No change was
observed in 97 (19.5%) patients, while 52 patients (10.4%) reported
a worsening in general health. EQ5D VAS score had paired sample
pre- and post-procedure responses for 530 patients. Here, improve-
ments were observed in 399 patients (75.3%), with no change in
85 patients (16.1%) and poorer post-procedure general health
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Figure 1 Number of patients reporting symptoms before and after ablation.
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Table 2 Symptom change by substrate
Heart racing Fatigue Heart flutter Dizziness Breathlessness Chest pressure
Percentage change in the number of patients reporting any symptoms following ablation (change in the number of patients)
All substrates 253.9% (256) 234.3% (149) 233.1% (136) 254.5% (192) 247.3% (168) 259.5% (185)
AF 247.8% (54) 236.5% (38) 236.2% (38) 254.3% (44) 240.5% (34) 249.2% (31)
AVNRT 264.6% (73) 248.4% (46) 225.8% (24) 266.7% (56) 263.8% (51) 280.9% (72)
C Flutter 250.9% (59) 231.0% (36) 241.6% (42) 242.4% (36) 243.4% (43) 245.3% (29)
Percentage of patients reporting an improvement in symptom severity following ablation (no. of patients)
All substrates 81.27% (408) 61.1% (291) 62.2% (305) 61.1% (208) 56.3% (259) 55.8% (251)
AF 75.2% (91) 65.5% (74) 68.1% (77) 76.1% (60) 51.2% (65) 39.0% (41)
AVNRT 95.6% (109) 63.6% (68) 62.2% (67) 68.2% (73) 68.2 (73) 83.0% (88)
C Flutter 77.2% (95) 67.5% (83) 68.7% (79) 56.5% (65) 57.3% (67) 39.8% (45)
PROMs for cardiac ablation procedures 1629
by guest on Septem
ber 28, 2015
D
ow
nloaded from
 
reported in 46 patients (8.7%). The EQ5D VAS score showed a
statistically significant difference pre- and post-procedure (19.09
mean improvement; P, 0.005); at a substrate level a statistically sig-
nificant improvement was also seen for all substrates, except ven-
tricular tachycardia (VT, P . 0.61); AT mean improvement 9.2
(P ¼ 0.002); AF mean improvement 21.09 (P ¼ ,0.005); AVN
mean improvement 18.31 (P ≤ 0.005); AVNRT mean improvement
17 (P ≤ 0.005); concealed accessory pathway (cAP) mean im-
provement 19.36 (P ¼ 0.001); oAP mean improvement 12.5 (P ¼
0.012) u/Flutter mean improvement 27.29 (P, 0.005); c/Flutter
mean improvement 19.69 (P, 0.005); VE mean improvement
27.73 (P ¼ 0.003).
Unexpected complications
A total of 213 unexpected post-procedural complications were
reported by 190 (33.4%) patients. These included clinical complica-
tions such as three cases of cardiac tamponade (incidence rate
0.5%), two transient ischaemic attacks (0.4%), and six strokes
(1.1%). Excessive bruising was reported by 75 patients (13.2%),
while “Other complications” including headache, bleeding at the
entry site, tachycardia, chest pain, and dizziness were reported by
79 patients (13.9%), with one femoral pseudoaneurysm reported.
Extended or re-hospitalizations for reasons including infections,
pneumonia, dyspnoea, pulmonary embolism, and myocardial infarc-
tionwere reportedby 46patients (8.1%). Themajorityof responders
were positive about the outcome of their ablation, with 413 of 545
patients (75.8%) reporting that the procedure had met their expec-
tations. Analysis of this outcome for the three most prevalent sub-
strate groups revealed that expectations were met in 72.4, 88.6,
and 72.8% of AF, AVNRT, and c/Flutter patients, respectively.
Non-responder data
Analysis of non-responder data usingCCADrecords found that non-
responders were significantly more likely to have had a completely
successful procedure (P, 0.024) (acute success assessedby the clin-
ician). This finding is suggestive that the PROMs may underestimate
the clinical benefit. The lengthof timebetween theprocedure and re-
ceiving the PROMwas also significant (P, 0.019), with patients who
sent the questionnaires at,9months post-proceduremore likely to
reply than those who sent it at ≥9 months. Age was also a significant
factor, with non-responders likely to be younger than responders
(P, 0.001). Gender, occurrence of complications, and urgency of
treatment (elective vs. emergency)didnot showanysignificantdiffer-
ences in response rates.
Issues and weaknesses
Responses highlighted weaknesses in some areas of the question-
naires. These included a lack of clarity with wording of some ques-
tions, e.g. for patients who had undergone a previous procedure
“Please state how many you have had” did not specify whether to
include the current procedure. Some patients indicated more than
one answer for some questions as it was not specified that only
one answer should be chosen. The questionnaires also attempted
to capture the number of work days (or equivalent) affected by
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Figure 2 Patient reported heart-racing severity before and after
ablation.
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arrhythmia, and this question was aimed at all patients. However, it
was ignored by a number of retired or unemployed patients who
noted that they felt this did not apply to them; some other questions
were also left blank when patients felt they were not applicable.
Comments added to questionnaires provided useful feedback. For
example, a number of patients wrote that although their symptoms
were unchanged since the procedure, they had been able to
reduce or stop their medication; others noted that they suffered
co-morbidities. Some patients commented that they were grateful
for the opportunity to feedback on the procedure, with some
adding remarks, including “I am very grateful for the operation that
up to now has totally cured my symptoms. The doctor and team
were fantastic and very professional. They made me feel very safe
whilst in their care and I am extremely grateful for their help” and
“I would like to say how impressed I was with both the quality of
care I received and the kindness shown to me both during and after
my cardiac cryoablation. The skill and professionalism of all the
staff was greatly appreciated”.
Discussion
Findings
The findings of the study are encouraging, and the high response
rate suggests that collectionof PROMs in this patient group is feasible.
The improvement in symptom occurrence and severity, reduction in
the impact onwork and social activities, and reduction in the number
of GP/hospital visits indicate that the procedure has a considerable
positive impact on the quality of life for the majority of patients. As
well as the impact of symptoms on patients’ functional abilities, the
pre-ablation responses illustrate the wider implications regarding
service use and work days lost. In general, the results of the newly
developed tools showed high correlation with the EQ5D. How-
ever, the newly developed tools showed increased sensitivity to
issues such as changes in patient symptoms and concerns, and provided
useful data to compare between arrhythmia substrates. It was also
able to identify complications and assess patient expectation.
Study limitations
As pre- and post-procedure questionnaires were sent out together,
the volume of questionnaires may have deterred some responders.
However, as the primary aim was to test acceptability and under-
standing of the questionnaires and the feasibility of gaining responses,
this limitation was felt to be acceptable. Furthermore, as this study
was not conducted in real time, some patients were completing the
questionnaires up to 16months post-procedure. This led to reliance
on patient memory, and some struggled to recall how they felt prior
to the procedure, while others may have given inaccurate answers,
potentially biased by treatment outcomes for example, leading to er-
roneous data. Some patients received additional treatment during
the time period or may have suffered from other health problems
making it difficult to differentiate between arrhythmia-associated
complications and non-related symptoms. In some cases, patients
stated that they experienced an initial improvement in symptoms fol-
lowing the ablation, followedbya subsequentdeterioration.Thismay
have been due to a natural disease progressionwhichwould not have
been picked up by the process if it had been administered in a
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traditional way. As with any PROMs it can be argued that the non-
responders may be those who benefitted least (or most) from the
procedure, again leading to skewed data.
Weakness of the tools
The weaknesses highlighted in the audit can largely be rectified by
simple rewording of affected questions; however, some areas
require more extensive work to clarify issues. This is the case in
areas including how to address “normal routine” in patients who
are retired or do not work, and how to encourage patients to com-
plete all fields evenwhen they feel a question does not apply to them.
Additional areas to consider for improving the questionnaire
include the insertion of questions relating to medications used to
identify changes in these following the procedure, and also informa-
tion regardingco-morbidities. Thiswill adddepthof understanding to
the questionnaires; particularly to the EQ5D which may show little
change following a highly successful ablation procedure if a patient
has unrelated medical problems. Using feedback from patients as
part of an iterative process of questionnaire improvement is an im-
portant stage in the validation process.
Strengths of the study
The audit received a satisfactory response rate, suggesting that the
length and content of the questionnaires were not unreasonable,
even in the format used where both pre-and post-procedure ques-
tionnaires were received together. Feedback received from patients
during telephone enquiries and via comments on the questionnaires
was useful and gave an insight into areas requiring clarification: a
useful mechanism to improve the tools. Patients were pleased to
have the opportunity to comment on the treatment they had
received.
High success rates for catheter ablation have been reported in the
literature, with up to 99% success in some studies.14 The feedback
received from patients in this study also suggests that ablation
affords a high level of patient satisfaction, while giving data in a
greater depth of detail. Overall, the results showed that cardiac abla-
tion leads to a significant improvement in symptoms in themajority of
patients; this supports its use as a technique for improving the quality
of life in patients suffering from cardiac arrhythmias. Improvements
seen in the EQ-5D VAS and Index scores (75.1 and 70.3% of patients
reported an improvement, respectively) compare well with those
observed in the National PROMs programme (during 2009–2010,
groin, hernia, hip replacement, knee replacement, and varicose vein
surgery saw VAS improvements of 39.1, 61.4, 50.8, and 39.8%, re-
spectively, with index score improvements in 50.5, 86.7, 77.9, and
51.6%, respectively15).
Conclusion
This pilot study has provided a solid foundation on which to build a
robust disease-specific PROM tool for cardiac ablation. The
processwas successfulwithhigh response andcompletion rates, sup-
porting the feasibility of collecting PROMs in this patient group. Al-
though this audit was only a preliminary part of the PROMs
development procedure, the responses are a useful part of the valid-
ation process and facilitate improvements to the tools and method
involved. The results of responses during these preliminary stages
are very encouraging and illustrate the benefits of performing
cardiac ablation in symptomatic patients. Further research is aimed
at psychometric testing and validation of the tool. Cardiac arrhyth-
mias have an adverse effect on the quality of life of many patients
and successful treatment can be life-enhancing.
Further research
Following the success of this audit, further work into this area has
been commissioned by the National Institute of Health and Care
Excellence. Based on the responses received, the questionnaires
have been updated and adapted into single pre- and post-procedure
documents. Ethical approval has been given and a two-phase study is
now underway (registered on the Clinical Trials website, reference:
NCT01672528). This comprises of patient interviews to test, im-
prove, and retest the questionnaires further and a postal survey
phase involving up to 600 patients from three study centres as part
of a prospective study. These patients will receive questionnaire pre-
ablation, at 8–16 weeks, post-procedure and at 1 and 5 years post-
procedure. The aim of this further study is to produce a validated
PROMs tool for use in the UK to collect data from ablation patients.
This will facilitate national measurement of the health change in
patients following ablation therapy, andwill allow statistical compari-
son between arrhythmia substrates and other subgroups.
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Peritricuspid reentrant ventricular tachycardia in Ebstein’s anomaly
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A 40-year-old woman with Ebstein’s anomaly of
the tricuspid valve presentedwith recurrent palpi-
tations. Electrocardiogram during the episode
showed a regular broad complex tachycardia at
150 beats per minute with left bundle branch ab-
normality morphology, left axis deviation and dis-
sociated, slower atrial activity.
During electrophysiology study, tachycardia
was induced by double ventricular extrastimuli.
Mapping of the right ventricle was performed
during tachycardia using an electroanatomical
three-dimensionalmapping system (CARTO, Bio-
sense Webster). Bipolar voltage map showed a
large scar in the basal inferior right ventricle.
Figure shows the activationmap in a modified pos-
terior view,with activation proceeding around the
tricuspid annulus and a ‘head meets tail’ pattern.
Radiofrequency ablation was done to interrupt
the isthmus between the scar and the annulus.
Tachycardia was no longer inducible after the
ablation.
Ventricular tachycardia is rare in Ebstein’s
anomaly. In our patient, scarring in the inferior,
atrialized portion of the right ventricle formed a
substrate for peritricuspid reentry. Reentry
around the tricuspid annulus has been previously described in patients with arrhythmogenic right ventricular dysplasia, but not, to our
knowledge, in Ebstein’s anomaly.
The full-length version of this report can be viewed at: http://www.escardio.org/communities/EHRA/publications/ep-case-reports/
Documents/Peritricuspid-reentrant-ventricular.pdf.
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